复发或转移性头颈部鳞状细胞癌的预后因素
本研究在327例「实际临床」复发或转移性头颈部鳞状细胞癌患者中验证Argiris预后分类,该分类基于体重下降、ECOG-PS、原发部位、肿瘤分化和既往放疗。全组中0-2个与≥3个不良特征患者的总生存(中位14 vs 10个月,P=0.03)和无进展生存(中位7 vs 5个月,P=0.02)均有显著差异。多因素分析显示复发部位和无病间期也是OS和PFS的显著预测因素。
要点
- Argiris预后模型在实际临床人群中得到验证。
- 0-2个与≥3个不良特征患者的中位OS为14 vs 10个月(P=0.03)。
- 多因素分析中复发部位和无病间期是OS和PFS的显著预测因素。
核心结论
- Argiris模型在「实际临床」人群中得到验证,并发现其他可能的预后因素。
研究设计与样本
- 主要分析纳入327例复发或转移性头颈部鳞状细胞癌患者;二次分析排除31例p16阳性和/或HPV阳性的口咽癌患者。
- 采用Kaplan-Meier法估计OS和PFS曲线,并进行多因素Cox分析。
主要发现
- 全组中0-2个与≥3个不良特征患者的中位OS为14 vs 10个月(P=0.03)。
- 全组中0-2个与≥3个不良特征患者的中位PFS为7 vs 5个月(P=0.02)。
- 多因素分析显示复发部位和无病间期是OS和PFS的显著预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In clinical trials of recurrent and metastatic head and neck carcinoma, Argiris et al have identified prognostic factors for overall survival (OS) and progression-free survival (PFS), weight loss, Eastern Cooperative Oncology Group performance status (ECOG-PS), tumor primary site, tumor differentiation, prior radiotherapy, deriving a two-group prognostic classification. This study evaluates Argiris's classification in "field-practice" patients. METHODS: The main analysis included 327 cases; a secondary analysis excluded 31 patients with oropharyngeal carcinoma (OPC) p16-positive and/or human papilloma virus (HPV)-positive. OS and PFS curves were estimated with the Kaplan-Meier method; multivariable Cox analyses were also performed. RESULTS: In the full series, OS was significantly different in patients with 0-2 and ≥3 adverse features (median, 14 vs 10 months; P = .03). PFS was statistically different in the two groups (median, 7 vs 5 months; P = .02). At a multivariable analysis investigating additional prognostic features, site of relapse and disease-free interval were significant predictors of OS and PFS. CONCLUSION: The Argiris's model was confirmed in a "field-practice" population. Moreover, we found additional putative prognostic factors.
引用
- Mirabile A, Miceli R, Calderone RG, et al. Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck. 2019. PMID: 30652392. doi:10.1002/hed.25636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。